Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-13
2006-06-13
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07060681
ABSTRACT:
The application describes ligands for binding targets, the ligands preferably including peptides having at least one sulfated or sulfonated amino acid. The ligand preferably specifically binds to heparin binding sites of biomolecules. Compositions, systems, and methods for making and using the ligands are described.
REFERENCES:
patent: 6037329 (2000-03-01), Baird et al.
patent: WO 01/98365 (2001-12-01), None
patent: WO 2005/034844 (2005-04-01), None
Folkman et al “Control of angiogenesis with synthetic heparin substitutes” Science, 1989, vol. 243, No. 4897, pp. 1490-1493.
Heather D. Maynard and Jeffrey A. Hubbell, “Identification of oligopeptide VEGF binders using a rationally designed combinatorial library approach”, Abstract for Chicago ACS Meeting, Aug. 2001, Chicago, Illinois.
Heather D. Maynard and Jeffrey A. Hubbell, “Discovery of Novel Oligopeptides for Controlled Release of Therapeutic Molecules Using a Rationally Designed Combinatorial Library Approach”, Poster, Plymouth, New Hampshire, Jul. 2001.
Kit S. Lam, “Application of Combinatorial library methods in cancer research and drug discovery”,Anti-Cancer Drug Design(1997), vol. 12, pp. 145-167.
Sandra Liekens, Daria Leali, Johan Neyts, Robert Esnouf, Marco Rusnati, Patrizia Dell'Era, Prabhat C. Maudgal, Erik De Clercq, and Marco Presta, “Modulation of Fibroblast Growth Factor-2 Receptor Binding, Signaling, and Mitogenic Activity by Heparin-Mimicking Polysulfonated Compounds”,Molecular Pharmacology(1999), vol. 56, pp. 204-213.
Christopher R. Parish, Craig Freeman, Kathryn J. Brown, Douglas J. Francis and William B. Cowden, “Identification of Sulfated Oligosaccharide-based Inhibitors of Tumor Growth and Metastasis Using Novelin VitroAssays for Angiogenesis and Heparanase Activity”,Cancer Research, vol. 59, pp. 3433-3441.
Gerhard Zugmaier, Marc E. Lippman and Anton Wellstein, “Inhibition by Pentosan Polysulfate (PPS) of Heparin-Binding Growth Factors Released From Tumor Cells and Blockage by PPS of Tumor Growth in Animals”,Journal of the National Cancer Institute, vol. 84, No. 22, Nov. 18, 1992, pp. 1716-1724.
Judah Folkman, Paul B. Weisz, Madeleine M. Joullié, William W. Li and William R. Ewing, “Control of Angiogenesis with Synthetic Heparin Substitutes”,Science, vol. 241, pp. 1490-1493.
Constant A. A. van Boeckel and Maurice Petitou, “The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antitbrombotics”,Angewandte Chemie(International Edition in English), vol. 32, No. 12, pp. 1671-1690.
E. de Raucourt, S. Mauray, F. Chaubet, O. Maiga-Revel, M. Jozefowics, A.M. Fischer, “Anticoagulant activity of dextran derivatives”, 1998.
Brett Feret, “A novel synthetic antithrombotic for prevention of venous thromboemblism”,Formulary, Dec. 2001, vol. 36, pp. 831-837.
J.M. Herbert, J.P. Hërault, A. Bernat, R.G.M. van Amsterdam, J.C. Lormeau, M. Petitou, C. van Boeckel, P. Hoffmann, and D.G. Meuleman, “Biochemical and Pharmacological Properties of SANORG 34006, a Potent and Long-Acting Synthetic Pentasaccharide”,Blood, vol. 91, No. 11, (Jun. 1, 1998), pp. 4197-4205.
Delphine Logeart-Avramoglou, Jacqueline Jozefonvicz, “Carboxymethyl Benzylamide Sulfonate Dextrans (CMDBS), A Family of Biospecific Polymers Endowed with Numerous Biological Properties: A Review”, pp. 578-590.
J.M. Herbert, J.P. Hérault, A. Bernat, R.G.M. van Amsterdam, G.M.T. Vogel, J.C. Lormeau, M. Petitou and D.G. Meuleman, “Biochemical and Pharmacological Properties of SANORG 32701”,American Heart Research, Circulation Report, vol. 79, No. 3.
J.R. Fromm, R.E. Hileman, E.E.O. Caldwell, J.M. Weiler, and R.J. Linhardt, “Pattern of Spacing of Basic Amino Acids in Heparin Binding Sites”,Archives of Biochemistry and Biophysics, vol. 343, No. 1, pp. 92-100.
Alfonso Bentolila, Israel Vlodavsky, Christine Haloun and Abraham J. Domb, “Synthesis and Heparin-like Biological Activity of Amino Acid-based Polymers”,Polymers for Advanced Technologies, vol. 11, (2000), pp. 377-387.
Socorro Vázquez Campos, Les P. Miranda and Morten Meldal, “Preparation of novelO-sulfated amino acid building blocks with improved acid stability for Fmoc-based solid-phase peptide synthesis,”The Royal Society of Chemistry, 2002, pp. 682-686.
Hua-Quan Miao, David M. Ornitz, Elena Aingorn, Shmuel A. Ben-Sasson, and Israel Vlodavsky, “Modulation of Fibroblast Growth Factor-2 Receptor Binding, Dimerization, Signaling and Angiogenic Activity by a Synthetic Heparin-mimicking Polyanionic Compound”,The Journal of Clinical Investigation, vol. 99, No. 7, pp. 1565-1575.
Ryo Muramatsu, Masashi Sasaki, Nobuo Watanabe, Yuso Goto, Toru Okayama, Eriko Nukui, Tadanori Morikawa and Hideya Hayashi, “Antithrombotic Effects of NF-6505, A Novel Anion-Binding Exosite Inhibitor”,Thrombosis Research, vol. 86, No. 6, pp. 453-460.
Wayne J. Fairbrother, Hans W. Christinger, Andrea G. Cochran, Germaine Fuh, Christopher J. Keenan, Clifford Quan, Stephanie K. Shirver, Jeffrey Y.K. Tom, James A. Wells, and Brian C. Cunningham, “Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site”,Biochemistry, vol. 37, pp. 17754-17764.
Ruth Tyler-Cross, Michael Sobel, Dalila Marques, and Robert B. Harris, “Heparin binding domain peptides of antithrombin III: Analysis by isothermal titration calorimetry and circular dichroism spectroscopy”,Protein Science, vol. 3, (1994), pp. 620-627.
Jack Hirsh, MD, Sonia S. Anand, MD, Jonathan L. Halperin, MD and Valentin Fuster, MD, Ph.D, “Guide to Anticoagulant Therapy: Heparin A Statement for Healthcare Professionals From the American Heart Association”,American Heart Association, Inc., Circulation, vol. 103, pp. 2994-3018.
Gideon Bosker, MD FACEP, “Current Versus Future Strategies for Prevention of DVT in Patients Undergoing Hip and Knee Surgery”,Orthopedic Clinical Consensus Reports, Oct. 12, 2001, pp. 1-12.
Gera Neufeld, Tzafra Cohen, Stela Gengrinovitch, and Zoya Poltorak, “Vascular endothelial growth factor (VEGF) and its receptors”,The FASEB Journal, vol. 13, Jan. 1999, pp. 9-22.
Fatima El Khadali, Gárard Hélary, Graciela Pavon-Djavid, and Véronique Migonney, “Modulating Fibroblast Cell Proliferation with Functionalized Poly(methyl metacrylate) Based Copolymers: Chemical Compositions and Monomer Distribution Effect”,Biomacromolecules, vol. 3, No. 1, 2002, pp. 51-56.
Hyman Engelberg, M.D., “Actions of Heparin That May Affect The Malignant Process”,Cancer, vol. 85, No. 2, Jan. 15, 1999, pp. 257-272.
Roseyyne Binétry-Tournaire, Caroline Demangel, Bernard Malavaud, Roger Vassy, Sylvie Rouyre, Michael Kraemer, Jean Plouët, Claude Derbin, Gérard Perret and Jean Claude Mazié, “Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis”,The EMBO Journal, vol. 19, No. 7, pp. 1525-1533.
Ishan Capila and Robert J. Linhardt, “Hearpin-Protein Interactions”,Angew. Chem. Int. Ed., vol. 41, 2002, pp. 390-412.
Massimo Cristofanilli, Chusilp Charnsangavej and Garbriel N. Hortobagyi, “Angiogenesis Modulation in Cancer Research: Novel Clinical Approaches”,Nature Reviews, vol. 1, Jun. 2002, pp. 415-426.
Rosa Crum, Sandor Szabo, and Judah Folkman, “A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment”,Science, vol. 230, Dec. 20, 1985, pp. 1375-1378.
R. Danesi, S. Del Bianchi, P. Soldani, A. Campagni, R.V. La Rocca, C.E. Myers, A. Paparelli & M. Del Tacca, “Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane”,Cancer, vol. 68, pp. 932-938.
Sandra Liekens, Johan Neyts, Bart Degrève, and Erik De Clercq, “The Solfonic Acid
Hubbell Jeffrey A.
Maynard Heather D.
Schoenmakers Ronald
Campell Bruce R.
Ecole Polytechnique Federale de Lausanne (EPFL)
Patterson Thuente Skaar & Christensen P.A.
Teller Roy
LandOfFree
Compositions and methods for use of bioactive agents derived... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for use of bioactive agents derived..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for use of bioactive agents derived... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3624914